Navigation Links
Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development
Date:7/21/2009

NEW YORK, July 21 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research has awarded research teams at nine biotech and pharmaceutical companies a total of $3.8 million for pre-clinical Parkinson's drug development projects. Funded investigations aim to push forward novel neuroprotective and improved symptomatic therapies as well as new strategies for addressing complications of treatment.

While MJFF accepts applications from industry under all of its programs, the Therapeutics Development Initiative (TDI) - first launched in 2006 - is the Foundation's only industry-exclusive funding stream. It is a key element of MJFF's strategy to 'de-risk' preclinical PD research for biotech and pharmaceutical companies, thus expanding industry investment in Parkinson's therapeutic development and helping push the most promising research to the next stage.

Projects selected for funding are listed below. Detailed information, including grant abstracts and researcher bios, is available on the Foundation's Searchable Database of Funded Grants. As with all MJFF grants, full funding is contingent on the achievement of predetermined, specific milestones and on researchers' agreement to make the results of their work available to the Parkinson's research community.

Neuroprotective Approaches

Pharmacodynamics of ReS9-S7, a first-in-class, disease-modifying drug candidate for treatment of Parkinson's disease

Gerard Griffioen, PhD, NV reMYND, Leuven, Belgium

Exploring curcumin and curcumin derivatives as putative epigenetic targets of histone deacetylase (HDAC) inhibition in Parkinson's disease

Lawrence Helson, MD, Sign Path Pharma, Inc., Quakertown, Pennsylvania

Assessment of the therapeutic efficacy of progranulin in a sub-chronic animal model of Parkinson's disease

Denis Kay, PhD, Neurodyn, Inc., Charlottetown, Prince Edward Island, Canada

Validation of LRRK2 as a drug target for treatment of Parkinson's disease using antisense technology

Alejandro Lloret, PhD, Isis Pharmaceuticals, Inc., Carlsbad, California

Optimizing lead series of small molecule inhibitors of LRRK2 to deliver tool compounds and clinical development candidates

Alastair D. Reith, PhD, GlaxoSmithKline, United Kingdom

A novel approach to characterize the distribution of a potentially therapeutic dominant-negative inhibitor of tumor necrosis factor in pre-clinical models of PD, and predict the scalability for an effective delivery of therapy in the human brain

Lisa Lynn Shafer, PhD, Medtronic Neuromodulation, Minneapolis, Minnesota

Pre-clinical development of a Parkinson's disease therapy using a glucagon-like peptide (GLP-1) receptor agonist

Kevin Tomaselli, PhD, Amylin Pharmaceuticals, Inc., San Diego, California

Symptomatic Approaches/Complications of Treatment

Effect of novel neuronal nicotonic receptor compounds on treatment of levodopa-induced dyskinesia in Parkinson's disease

Kristen Jordan, PhD, Targacept, Winston-Salem, North Carolina

Optimization of MOR antagonists for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease

Patrick Little, PhD, Adolor Corporation, Exton, Pennsylvania

TDI is launched bi-annually with applications accepted each spring and fall. It has been enthusiastically received by industry researchers. To date the Foundation has awarded $16.5 million total for 33 industry-led projects under the initiative.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today. To date, the Foundation has funded $149 million in research. For more information on TDI and the Foundation's industry strategy, please visit www.michaeljfox.org/industry.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
11. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... WI (PRWEB) , ... October 13, 2017 , ... As ... in medicine known as “patient engagement.” The patient is doing more than filling out ... partners. , “There is an increasing emphasis in health care and research on ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... process to promote standards of excellence for the field of eating disorders, announces ... 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... QUEENS, N.Y (PRWEB) , ... October 13, 2017 , ... ... recently became a member of ElderCounsel, a national organization of elder law and special ... constantly changing laws and rules. It also provides a forum to network with elder ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... Texas , Oct. 6, 2017   Provista, ... with more than $100 billion in purchasing power, today ... news and information. The Newsroom is the ... and industry trends, infographics, expert bios, news releases, slideshows ... having access to a wealth of resources at their ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... announces the European launch of their new low volume, high throughput ... Cambridge, U.K on October 4th. The new ... unprecedented speed and sensitivity while using far less sample volume through ... ... ...
Breaking Medicine Technology: